Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Overview
Olvimulogene nanivacirepvec is an oncolytic virus developed by Genelux. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Olvi-Vec is an engineered oncolytic vaccinia virus. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471, plans to enrol 186 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Olvimulogene nanivacirepvec" OR ABSTRACT:"Olvimulogene nanivacirepvec" OR TITLE:"GL-ONC1 and GLV-1h68" OR ABSTRACT:"GL-ONC1 and GLV-1h68" OR TITLE:"Olvi-Vec" OR ABSTRACT:"Olvi-Vec" OR TITLE:"GL-ONC" OR ABSTRACT:"GL-ONC" OR TITLE:"GLV-1h68" OR ABSTRACT:"GLV-1h68") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Olvimulogene nanivacirepvec, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPalacaparib
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentXNW27011
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentHLX43
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentIN10018
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentSaruparib
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJK08
Shares Ovarian cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentVRN110755
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentIMP4927
Shares Ovarian cancer and the tags pipeline, ctgov-ingest.